The validation of surrogate endpoints has been studied by Prentice, who presented a definition as well as a set of criteria that are equivalent if the surrogate and true endpoints are binary. Freedman et al. supplemented these criteria with the so-called proportion explained. Buyse and Molenberghs proposed to replace the proportion explained by two quantities: (1). the relative effect, linking the effect of treatment on both endpoints, and (2). the adjusted association, an individual-level measure of agreement between both endpoints. In a multiunit setting, these quantities can be generalized to a trial-level measure of surrogacy and an individual-level measure of surrogacy. In this paper, we argue that such a multiunit approach should be a...
This article extends the work of BUYSE et al. (2000) on the validation of surrogate endpoints in a m...
Thesis (Ph.D.)--Boston UniversityPLEASE NOTE: Boston University Libraries did not receive an Authori...
A common problem of interest within a randomized clinical trial is the evaluation of an inexpensive ...
A surrogate endpoint is intended to replace a clinical endpoint for the evaluation of new treatments...
Abstract–In spite of medical and methodological advances, the identification of good surrogate endpo...
Part of the recent literature on the evaluation of surrogate endpoints starts from a multi-trial app...
OBJECTIVE: A schema was recently proposed for assessing the levels of evidence for surrogate validit...
The last couple of decades have seen a large amount of activity in the area of surrogate marker and ...
Part of the recent literature on the validation of biomarkers as surrogate endpoints proposes to und...
Randomized clinical trials with rare primary endpoints or long duration times are costly. Because of...
Part of the recent literature on the validation of biomarkers as surrogate endpoints proposes to und...
In randomized clinical trials, the evaluation of potential surrogate endpoints is very important, s...
Background: In recent years the use of surrogate end points (S) has become an interesting issue. In ...
The relationship between association and surrogacy has been the focus of much debate in the surrogat...
A surrogate end point is often used to evaluate the effects of treatments or exposures on the true e...
This article extends the work of BUYSE et al. (2000) on the validation of surrogate endpoints in a m...
Thesis (Ph.D.)--Boston UniversityPLEASE NOTE: Boston University Libraries did not receive an Authori...
A common problem of interest within a randomized clinical trial is the evaluation of an inexpensive ...
A surrogate endpoint is intended to replace a clinical endpoint for the evaluation of new treatments...
Abstract–In spite of medical and methodological advances, the identification of good surrogate endpo...
Part of the recent literature on the evaluation of surrogate endpoints starts from a multi-trial app...
OBJECTIVE: A schema was recently proposed for assessing the levels of evidence for surrogate validit...
The last couple of decades have seen a large amount of activity in the area of surrogate marker and ...
Part of the recent literature on the validation of biomarkers as surrogate endpoints proposes to und...
Randomized clinical trials with rare primary endpoints or long duration times are costly. Because of...
Part of the recent literature on the validation of biomarkers as surrogate endpoints proposes to und...
In randomized clinical trials, the evaluation of potential surrogate endpoints is very important, s...
Background: In recent years the use of surrogate end points (S) has become an interesting issue. In ...
The relationship between association and surrogacy has been the focus of much debate in the surrogat...
A surrogate end point is often used to evaluate the effects of treatments or exposures on the true e...
This article extends the work of BUYSE et al. (2000) on the validation of surrogate endpoints in a m...
Thesis (Ph.D.)--Boston UniversityPLEASE NOTE: Boston University Libraries did not receive an Authori...
A common problem of interest within a randomized clinical trial is the evaluation of an inexpensive ...